NCT04535427

Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

To investigate the role of L-arginine supplementation in the treatment of DMARDs-refractory moderate to severe rheumatoid arthritis

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	L-arginine	Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
DRUG	Placebo	Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Timeline

• Start date: 2021-01-01
• Primary completion: 2023-01-01
• Completion: 2023-12-31
• First posted: 2020-09-02
• Last updated: 2020-09-02

Locations

1 site across 1 country: China